title: Excellent tolerance to cilnidipine in hypertensives with amlodipine - induced edema.
abstract: BACKGROUND
  Ankle edema is a common adverse effect of amlodipine, an L-type calcium channel blocker (CCB). Cilnidipine is a newer L/N-type CCB, approved for treatment of essential hypertension.
  
  
  OBJECTIVE
  This study was designed to determine whether cilnidipine can produce resolution of amlodipine-induced edema while maintaining adequate control of hypertension.
  
  
  METHODS
  A prospective study was performed on 27 patients with essential hypertension with amlodipine-induced edema. Concomitant nephropathy, cardiac failure, hepatic cirrhosis, or other causes of edema, and secondary hypertension were excluded by appropriate tests. Amlodipine therapy was substituted in all the cases with an efficacy-equivalent dose of cilnidipine. Clinical assessment of ankle edema and measurement of bilateral ankle circumference, body weight, blood pressure, and pulse rate were performed at onset of the study and after 4 weeks of cilnidipine therapy.
  
  
  RESULTS
  At completion of the study, edema had resolved in all the patients. There was a significant decrease in bilateral ankle circumference and body weight (P < 0.001). There was no significant change in mean arterial blood pressure and pulse rate.
  
  
  CONCLUSIONS
  Therapy with cilnidipine resulted in complete resolution of amlodipine-induced edema in all the cases without significant worsening of hypertension or tachycardia. Cilnidipine is an acceptable alternative antihypertensive for patients with amlodipine-induced edema.
authors: Department of Cardiology, Kasturba Medical College, Manipal, Karnataka, India.
authors: Ranjan
authors: R
authors: Shetty
authors: G
authors: G
authors: Vivek
authors: Kushal
authors: K
authors: Naha
authors: Anil
authors: A
authors: Tumkur
authors: Abhinav
authors: A
authors: Raj
authors: K L
authors: KL
authors: Bairy
keywords: Ankle edema; Calcium channel blocker; Cilnidipine; Hypertension; L/N-type calcium channel
references: Curr Hypertens Rev. 2006 May 1;2(2):103-111
references: 19823601
references: J Hum Hypertens. 2001 Jul;15(7):455-61
references: 11464254
references: J Int Med Res. 2012;40(4):1417-28
references: 22971493
references: Am J Hypertens. 1990 Jun;3(6 Pt 1):491-5
references: 2369499
references: Blood Press. 2002;11(2):95-100
references: 12035878
references: Blood Press Suppl. 1996;5:24-8
references: 8973789
references: J Hypertens. 2007 Oct;25(10):2178-83
references: 17885563
references: Am J Hypertens. 2002 Nov;15(11):932-40
references: 12441211
references: Eur J Clin Pharmacol. 1995;48(1):1-7
references: 7621840
references: Clin Ther. 1997 Nov-Dec;19(6):1368-78
references: 9444446
references: Cardiovasc Hematol Disord Drug Targets. 2012 Sep;12(1):56-62
references: 22746347
references: Hypertens Res. 2004 Jun;27(6):379-85
references: 15253102
references: Clin Exp Hypertens. 2010;32(6):400-5
references: 20828221
references: Am Heart J. 1989 Nov;118(5 Pt 2):1114-9; discussion 1119-20
references: 2573265
references: Int Heart J. 2008 Nov;49(6):723-32
references: 19075488
references: Ann Pharmacother. 2005 Apr;39(4):761-3
references: 15728328
references: Am J Hypertens. 1996 Sep;9(9):895-901
references: 8879346
references: Am J Hypertens. 2010 Sep;23(9):1023-30
references: 20725056
references: J Hypertens Suppl. 1989 Sep;7(4):S161-7; discussion S168
references: 2681592
references: Drugs. 1999;57 Suppl 1:27-9
references: 10529080
references: Kidney Int. 2007 Dec;72(12):1543-9
references: 17943080
references: Drugs. 2001;61(12):1777-99
references: 11693466
references: Am J Hypertens. 1995 Jan;8(1):87-9
references: 7734104
references: Kidney Int. 2006 Jul;70(1):151-6
references: 16710356
references: Am J Hypertens. 1997 Mar;10(3):250-60
references: 9056681